TIDMYGEN
RNS Number : 1017T
Yourgene Health PLC
23 March 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Share option exercises and awards
Manchester, UK - 23 March 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces an exercise
and an additional award of share options.
Exercise of options
The Company has received notification for the following exercise
of options, generating in aggregate proceeds of
approximately GBP205,000 ("Options Exercise") to the Company:
N umber of options Exercise price
exercised
320,000 10.00 pence
------------------- ---------------
33,333 10.25 pence
------------------- ---------------
2,200,000 7.75 pence
-------- ------------------- ---------------
Total: 2,553,333
------------------- ---------------
Application will be made to the London Stock Exchange to admit
the 2,553,333 new ordinary shares resulting from the Options
Exercise to trading on AIM. Admission of the new ordinary shares is
expected to occur on or around 26 March 2021. The new ordinary
shares will rank pari passu with the existing ordinary shares.
Award of options
The Company has today issued 1,400,000 options over Ordinary
Shares of 0.1p under the Company's Enterprise Management Incentive
(EMI) and unapproved share option schemes to a number of
individuals to reflect recent management changes.
In addition to the above, the Company has identified an
administrative error which occurred in the award of 750,000 options
announced on 25 September 2020, and a further 400,000 options
issued and announced on 19 June 2020. These 1,150,000 options have
been cancelled and reissued with identical terms.
Options granted 2020 EMI Options Total options
22 March 2021 cancelled & now granted
reissued
Dr Joanne Mason* 250,000 750,000 1,000,000
---------------- ----------------- --------------
Other 1,150,000 400,000 51,359,232
---------------- ----------------- --------------
Total 1,400,000 1,150,000 61,359,232
---------------- ----------------- --------------
*Dr Joanne Mason is a director of the Company.
The options are exercisable in three tranches over three
financial years and are subject to certain performance conditions.
The options awarded on 22 March 2021 are exercisable up to 21 March
2031, at a price of 18 pence per share.
Total Voting Rights
For the purpose of the Disclosure and Transparency Rules,
following the issue of shares to satisfy exercised share options
detailed above the enlarged issued share capital of the Company
will comprise 723,063,283 ordinary shares of 0.1p each. The Company
does not hold any ordinary shares in treasury. The above figure may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company, under
the Disclosure and Transparency Rules.
Following the award of these new options, and taking into
account lapsed options and those cancelled and reissued, the
Company has 61,359,232 shares under option, a further 54,332,541
shares under warrant to Thermo Fisher and 10,249,624 shares in a
Canadian subsidiary which are exchangeable for shares in the
Company. The Company's investor website provides details of these
warrants and exchangeable shares.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Joanne Mason
------------------------------------ --------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------
a) Position/status Director
------------------------------------ --------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------
a) Name Yourgene Health plc
------------------------------------ --------------------------------------------
b) LEI 213800UUIT8BZE7QEH33
------------------------------------ --------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------------
a) Description of the Options over ordinary shares of 0.1p
financial instrument, each
type of instrument
Identification code ISIN: GB00BN31ZD89
b) Nature of the transaction Grant of options
------------------------------------ --------------------------------------------
c) Price(s) and volume(s)
--------------- ----------------
Price(s) Volume(s)
--------------- ----------------
7.75p 250,000
18.0p 750,000
--------------- ----------------
d) Aggregated information
- Aggregated volume 1,000,000
- Price 7.75p / 18.0 p
e) Date of the transaction 22 March 2021
------------------------------------ --------------------------------------------
f) Place of the transaction UK
------------------------------------ --------------------------------------------
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDKBBNFBKDFNB
(END) Dow Jones Newswires
March 23, 2021 03:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024